MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • 2016 International Congress

    Drug safety in the pharmacotherapy of Parkinson’s disease

    S. Müller-Rebstein, C. Trenkwalder, J. Ebentheuer, C. Culmsee, G. Höglinger (Kassel, Germany)

    Objective: Detection of the most common and most serious drug-related problems in the pharmacotherapy of Parkinson's disease (PD), particularly with focus on interactions and contraindications…
  • 2016 International Congress

    Healthcare burden of Parkinson’s disease

    M. Tagliati, A.T. Connolly (Los Angeles, CA, USA)

    Objective: Evaluate healthcare costs for a cross-section of patients with Parkinson's disease (PD). Background: PD is a progressive, nonfatal condition with an increasing societal cost…
  • 2016 International Congress

    Dophaminergic therapy and its influence on the olfactory function of patients with Parkinson’s disease

    O. Izhboldina, I. Zhukova, N. Zhukova, V. Alifirova, A. Latypova, M. Nikitina, Y. Mironova (Tomsk, Russia)

    Objective: The aim of this study was to investigate effects of dophaminergic therapy on olfaction of patients with Parkinson's disease. Background: Influence of dopaminergic drugs…
  • 2016 International Congress

    In idiopathic Parkinson’s disease: The effect of using L-dopa on peripheral nerves

    M.E. Temir, F. Genç, Y. Biçer Gömceli, A. Yaman, A. Aybar, E. Karaçay (Antalya, Turkey)

    Objective: Idiopathic Parkinson's disease (IPD) is a chronic neurodegenerative disorder. Most of the clinicians believe that it is limited with motor and cognitive disorders. However,…
  • 2016 International Congress

    An atypical case of adult-onset, levodopa-responsive, paroxysmal dystonia

    V.N. Holiday (Portland, OR, USA)

    Objective: To describe a case of adult-onset, levodopa-responsive, paroxysmal dystonia. Background: Adult-onset dystonia cases account for at least 90% of primary dystonia, however, less than…
  • 2016 International Congress

    The novel COMT-inhibitor ODM-104 and optimized carbidopa in combination with modified release levodopa reduce levodopa fluctuation and increase minimum concentrations in healthy subjects, when compared to the standard carbidopa/levodopa/entacapone combination

    J. Ellmen, J. Tuunainen, A. Holopainen, T. Sarapohja, M. Scheinin (Turku, Finland)

    Objective: To evaluate the plasma pharmacokinetics (PK) of orally administered modified release (MR) levodopa in combination with the aromatic L-amino acid decarboxylase inhibitor carbidopa and…
  • 2016 International Congress

    Effect of patient characteristics on motor function in response to 35–50 mg of inhaled levodopa (CVT-301) in patients with Parkinson’s disease: Results from a phase 2b study

    P.A. LeWitt, M.I. Freed, M. Leinonen, A. Sedkov, H. Murck (West Bloomfield, MI, USA)

    Objective: To examine whether the response to an inhaled levodopa formulation (CVT-301; at 35 and 50 mg per dose) is dependent on baseline patient characteristics.…
  • 2016 International Congress

    Characterization of burning mouth syndrome in patients with Parkinson’s disease

    P.J. Blanchet, D. Bonenfant, P.H. Rompré, N. Rei, N. Jodoin, V.L. Soland, V. Rey, C. Brefel-Courbon, F. Ory-Magne, O. Rascol (Montreal, QC, Canada)

    Objective: To determine the prevalence and characteristics of burning mouth syndrome (BMS) in a Parkinson's disease (PD) population through a self-administered survey. Background: The majority…
  • 2016 International Congress

    Intrastriatal injection of ionomycin profoundly changes motor response to L-DOPA and its underlying molecular mechanisms

    C. Han, S. Nie, G. Chen, K. Ma, N. Xiong, Z. Zhang, Y. Xu, T. Wang, S.M. Papa, X. Cao (Wuhan, People's Republic of China)

    Objective: We investigated whether intrastriatal injection of ionomycin to hemiParkinsonian rats produced changes in L-DOPA responses including LID and analyzed the effects of ionomycin on…
  • 2016 International Congress

    Prevalence of orthostatic hypotension after a low subacute levodopa dose in patients with parkinsonism

    G. Calandra-Buonaura, L. Sambati, I. Gessaroli, A. Turrini, R. Terlizzi, G. Giannini, P. Guaraldi, P. Cortelli (Bologna, Italy)

    Objective: To evaluate the prevalence of orthostatic hypotension (OH) after a low subacute levodopa (LD) dose in patients with diagnosis of Parkinson's disease (PD) or…
  • « Previous Page
  • 1
  • …
  • 67
  • 68
  • 69
  • 70
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley